Thank you for your interest in the QOLIE-AD-48. Copyright for the QOLIE-AD-48 and all translations are held by the QOLIE Development Group: The QOLIE Development Group grants permission to use the QOLIE-AD-48 in accordance with the following conditions that shall be assumed by all to have been agreed as a consequence of accepting and using this document:

1. Copyright Statement to be printed on every QOLIE-AD-48 (v.1):

QOLIE-AD-48 (v.1) copyright by the QOLIE Development Group. (Cramer et al., Epilepsia, 1999). All rights reserved.

2. When the QOLIE-AD-48 is described in a publication, the citation should be listed as:

3. Changes to the QOLIE-AD-48 may not be made without the written permission of the QOLIE Development group. Any such changes shall be clearly identified as having been made by the recipient. This restriction is necessary to maintain the structural integrity of the original instrument.

4. The user accepts full responsibility, and agrees to indemnify and hold the QOLIE Development Group harmless, for the accuracy of any translations of the QOLIE-AD-48 into another language and for any errors, omissions, misinterpretations, or consequences thereof.

5a. Academic groups requesting use of QOLIE-AD-48 translations are given automatic permission for use with one copy of each questionnaire as requested.

5b. Non-Academic groups interested in using the QOLIE-AD-48 translations should contact Joyce.Cramer@gmail.com for information about licensing and fees. No other group may provide copies of the questionnaires for nonacademic use.

6. Translation and cross-cultural adaptation of all instruments is allowed if the user agrees to provide a copy of the new version (paper and electronic) and information about the conditions of translation to Joyce.Cramer@gmail.com when it is completed. All versions will be archived for distribution on request. The QOLIE Development Group will hold the copyright for all language versions

7. The user agrees to notify the QOLIE Development Group of any publications in which QOLIE-AD-48 data are presented. This information will be listed in a bibliography.

All questions about use and licensing should be referred to Joyce.Cramer@gmail.com for the QOLIE Development Group.
License Request: QOLIE-AD-48

Date: ____________

Sponsor Name: Cyberonics

Clinical Trial Name: ASCEND________________

Clinical Trial Number: E40______________

Language(s) Requested:
US English, US Spanish

Fee per clinical trial: \(1 \times 2500 = \$2500\)
Fee per language: \(2 \times 200/each = \$400\)
Total Fee: \$2900

Purchase Order Number: ____________

Address for Invoice:
Cyberonics, Inc
100 Cyberonics Blvd.
Houston, Texas 77058

Person Responsible for Payment (name, email address):

Signature of Sponsor or Agent: __________________________ Date: ____________

Cyberonics

Name of Sponsor or Agent: Peter.Sears@cyberonics.com
email address

Make payments to:
Epilepsy Study Consortium
c/o Sterling Foundation Management
Tax ID#: 20-4950952

Wire instructions:

Bank name: Wells Fargo Bank
Acct name: Epilepsy Study Consortium
Acct number: 2000024653334
Bank address: 2575 John Milton Dr., Herndon, VA 20171, USA
Routing number: 121000248
Swift code: WFBUS6F

(Reference: QOLIE-CYB)
Licensing Approved:

Joyce A. Cramer
joyce.cramer@gmail.com
For the QOLIE Development Group

Please this form to joyce.cramer@gmail.com for licensing before instruments/translations are provided. If additional instruments/translations are needed after the initial request, submit either a new Purchase Order or information that the original Purchase Order has been increased to accommodate the change.